chronic hepatitis b virus prospects for...
TRANSCRIPT
-
CHRONIC HEPATITIS B VIRUSProspects for Cure
Patrick T. F. KennedyReader in Hepatology & Consultant Hepatologist
Blizard Institute, Barts and The London SMD, QMUL, London
VIRAL HEPATITIS and CO-INFECTION with HIVBucharest, Romania, 6-7 October, 2016
-
350 million people worldwide
with CHB
80% of deaths in those infected at birth/early
childhood
25% of those infected in childhood develop
cirrhosis or HCC
>600,000 deaths per year
Chronic HBV Infection
-
Unmet challenges in HBV therapy
2
3
4
Strategies to achieve HBsAg loss and ‘cure’1
Defining treatment endpoints
Reducing the risk of HCC
Finite therapy options
-
Locarnini & Zoulim, Anitvir Ther 2010
Chronic HBV Infection
-
NUC target
Chronic HBV Infection
Locarnini & Zoulim, Anitvir Ther 2010
-
NUC target
Ideal therapytarget
Chronic HBV Infection
Locarnini & Zoulim, Anitvir Ther 2010
-
Natural history & disease phase
-
0
HBeAgAnti-HBe
HB
V D
NA/
HB
sAg
(log 1
0IU
/ml)
ALT (IU/L)
IMMUNE TOLERANT IMMUNE CLEARANCE IMMUNE CONTROL IMMUNE ESCAPE
ALT HBV DNA
Natural History & Disease Phase
adapted from Gill & Kennedy; Clin Med 2015
-
0
HBeAgAnti-HBe
HB
V D
NA/
HB
sAg
(log 1
0IU
/ml)
ALT (IU/L)
IMMUNE TOLERANT IMMUNE CLEARANCE IMMUNE CONTROL IMMUNE ESCAPE
ALT HBV DNA HBsAg
Natural History & Disease Phase
adapted from Gill & Kennedy; Clin Med 2015
-
Is our current understanding of natural history & disease phase
accurate?
-
Evidence of immune activity in the ‘immune tolerant’ disease phase
Kennedy/Bertoletti et al., Gastroenterology 2012
0
2
4
6
8
10
IT CA
-
Age (Years)
% C
D12
7lo
w P
D1+
CD
8 T
cel
ls
0 20 40 60 800
2
4
6
10
14
18P = .006
Age (Years)%
CD
127l
ow
PD
1+ C
D4
T c
ells
0 20 40 60 800
2
4
6
8P = .4383
Evidence of immune activity in the ‘immune tolerant’ disease phase
Kennedy/Bertoletti et al., Gastroenterology 2012
-
Evidence of liver damage in the ‘immune tolerant’ disease phase
Mason/Kennedy et al., Gastroenterology 2016
-
Nuclear core positive hepatocytes differentiate ‘immune tolerant’ disease
Mason/Kennedy et al., Gastroenterology 2016
-
Clonal hepatocyte expansion in ‘immune tolerant’ disease
Mason/Kennedy et al., Gastroenterology 2016
-
Redefining disease phase in CHB
Bertoletti & Kennedy, Cell & Mol.Immunol 2014
Immune Tolerance Immune Clearance
Non-Inflammatory Inflammatory
-
Treatment & management strategies
-
Current Treatment Regimes
Peg-IFN
NUCs
• Immunomodulatory agent• HBsAg decline or loss• Moderate rate of relapse• Finite therapy• Use of stopping rules
• Excellent viral suppression• Long term therapy• High barrier to resistance• Poor HBsAg reduction• ? Treatment endpoints
-
HBV Treatment regimesNucleos(t)ide Analogues (NUCs)
Marcellin et al, Lancet 2015; Chang, et al. Hepatology 2010
TENOFOVIR ENTECAVIR
-
Current therapies are non-curative
• Peg-IFN sustained immune control, but only in a minority of patients1
• HBeAg-negative & positive disease: – limited decline in HBsAg during NUC monotherapy2
• Long-term viral suppression is achieved, but sustained immune control following treatment cessation is limited3
1. EASL guidelines. J Hepatol 2012;57:167–85; 2. Zoutendijk R, et al. J Infect Dis 2011;204(3):415–8; 3. Hadziyannis SJ, et al. Gastroenterology 2012;143:629–36.
-
What are the available options…..
-
What are the available options…..
Sequential therapy strategies
Combination therapies
Discontinuation of NUCs
1
2
3
-
Sequential NUC Therapy
* p=
-
Sequential NUC Therapy
* p=
-
What are the available options…..
Sequential therapy strategies
Combination therapies
Discontinuation of NUCs
1
2
3
-
What are the available options…..
Sequential therapy strategies
Combination therapies
Discontinuation of NUCs
1
2
3
-
Can NUCs be discontinued after a period of consolidation therapy following HBeAg seroconversion?
HBeAg positive disease
-
Can NUCs be discontinued after a period of consolidation therapy following HBeAg seroconversion?
HBeAg positive disease
-
HBeAg negative disease
-
HBeAg Negative patientsVirally suppressed >24 months
No evidence of cirrhosis
4 weekly collection:Routine laboratory tests
PBMC
Immunoprofilingby CyTOF
mRNA expression By NanoString
by CyTOF
T cell phenotypingby flow cytometry
Ag-specific T cell analysisex vivo by CyTOFby flow cytometry
Ag-specific T cell analysis after in vitro expansion by Elispot
HBeAg negative diseaseImmune Profiling Study
-
Patient Profiles
on NUC off NUC
controllers: n = 2viral rebound: -hepatic flare: -
partial controllers: n = 11viral rebound: +hepatic flare: -
flare: n = 6viral rebound: +hepatic flare: +
Non-Flare Flare
Rivino*, Le Bert*, Gill*, et al., Manuscript in preparation* equal contribution
-
SFC
/105
cells
SFC
/105
cells
Increased frequency of HBV-specific T cell responses in ‘non-flare’ vs. flare patients prior to NUC discontinuation
* equal contribution Rivino*, Le Bert*, Gill*, et al., Manuscript in preparation
-
Novel Strategies for HBsAg loss
Bertoletti & Rivino, Curr Opin Infect Dis., 2014
-
Selective oral TLR Agonists in CHBTLR agonists enhance:•Production of IFN-γ and inflammatory cytokines like IL-12•Upregulation of costimulatory molecules such as CD80 and CD86•Induction of interferon stimulated genes
Gs-9620, an oral TLR7 agonist in development for chronic
viral hepatitis has demonstrated a potential for
induction of an antiviral response with an acceptable
adverse event profile
GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees.Lanford et al Gastroenterology 2013
Gane et al, J Hepatol 2015Phase 1b safety, pharmacokinetics and pharmacodynamics of GS-9620
-
GS-4774 (Tarmogen)
Stubbs, et al. Nat Med 2001; Cereda, et al. Vaccine 2011; Francis et al Vaccine 2015
CD4+
CD8+
GS-4774
APC
M X Large S (env) Core His 6
GS-4774 Recombinant Antigen
C8F17 fluorocarbon chain
DensigenTM
• ~ 30-40 amino acids long peptides• CD4+/CD8+ T cell epitopes • Net positive charge/Hydrophobicity
-
Effective T cells control virus Exhausted T cells loose control of virus
CD8 T cells
Infected hepatocytes Infected hepatocytes
INF-γTNF-αIL-2
GranzymePerforin
?Checkpoint blockade
Reversal of T cell exhaustion
The goal of checkpoint inhibitors
-
Lessons from cancer checkpoint inhibitor trials: PD-1
APC
PD-1PD-L1
Exhausted T cell Re-invigorated T cell
CytotoxicityPD-1/-L1blockade
APC
-
Lessons from woodchuck hepadnaviral infection
• Boosting of T and B cell immunity• Sustained viral suppression and sAg seroconversion
Combining PD-1 blockade with therapeutic vaccination
-
Summary of future drug targets for HBV therapies
-
Summary• Better understanding & re-definition of disease phase in
CHB is central to better treatment outcomes
• Long term on-treatment viral suppression is standard ofcare – but suboptimal
• Strategies to target cccDNA & achieve global immunerestoration will be critical to delivering cure in CHB
-
ACKNOWLEDGEMENTSRoyal London Hospital
Louise Payaniandy, Jo Schulz, Sally Thomas, Deva Payaniandy,
William Tong
Dimitra Peppa, Lorenzo Micco, Harsimran D. Singh,
Mala K. Maini
Graham R.FosterJyoti Hansi
Upkar S. Gill
Samuel Litwin,Yan Zhou, Suraj Peri
William Mason
Fox Chase Cancer Centre
Blizard Institute, QMULRayne Institute, UCL Duke, NUS/SICS A* Star
Elena Sandalova, Juandy Jo, Laura Rivino, Nina Le Bert, Evan Newell,
Antonio Bertoletti
ILS, Kings College
Oltin Pop, Ivana CareyAlberto Quaglia
Dianummer 1Dianummer 2Dianummer 3Dianummer 4Dianummer 5Dianummer 6Dianummer 7Dianummer 8Dianummer 9Dianummer 10Dianummer 11Dianummer 12Dianummer 13Dianummer 14Dianummer 15Dianummer 16Dianummer 17Dianummer 18Dianummer 19Dianummer 20Dianummer 21Dianummer 22Dianummer 23Dianummer 24Dianummer 25Dianummer 26Dianummer 27Dianummer 28Dianummer 29Dianummer 30Dianummer 31Dianummer 32Dianummer 33Dianummer 34Dianummer 35Dianummer 36Selective oral TLR Agonists in CHB�GS-4774 (Tarmogen)�Dianummer 39Dianummer 40Dianummer 41Dianummer 42Dianummer 43Dianummer 44